9 October 2012
EARLY ADVANTAGE FUND INVESTS £75,000 IN ABGENTIS
Abgentis will receive £75,000 from the Midven’s Early Advantage Fund in up to three milestone-driven tranches to establish proof of concept.
The money will be used to generate a package of pre-clinical proof-of-concept information to support the licensing of the programme to established pharmaceutical companies.
Dr Andrew Muir, a director of Midven and investment director of the Early Advantage Fund who has joined the Board of Abgentis said: “Lloyd has an excellent understanding of the technology and needs in the field of novel antibacterials and our funding will enable the company to validate its novel approach”